Stepwise IOP-Lowering Therapy: Drug Classes, Combinations, and When to Escalate
Start with a target IOP and a regimen the patient can follow
Glaucoma pharmacotherapy begins with setting a target intraocular pressure (IOP) based on baseline, severity of damage, rate of progression, life expectancy, and risk factor profile. A common starting framework is a 20–30% reduction from untreated baseline for early to moderate POAG, with lower targets for more advanced disease, rapid progressors, or normal-tension glaucoma (NTG). The target should be documented and reassessed at each follow-up.
Equally important is selecting a regimen the patient can realistically maintain. Adherence is the most common point of failure in glaucoma care. Starting with a once-daily medication, confirming technique and understanding, and escalating deliberately helps build a sustainable regimen before complexity overwhelms the patient.
Prostaglandin analogs: first-line for most open-angle patients
In the absence of contraindications, prostaglandin analogs (PGAs) are the standard first-line therapy for primary open-angle glaucoma (POAG) and ocular hypertension. They increase uveoscleral outflow and typically achieve 25–33% IOP reduction with once-nightly dosing, which supports adherence compared with multi-dose regimens.
Commonly used PGAs include latanoprost (Xalatan), travoprost (Travatan Z), bimatoprost (Lumigan), and tafluprost (Zioptan). Tafluprost is notable as a preservative-free PGA option for patients with ocular surface disease or BAK sensitivity.
Prostaglandin-associated periorbitopathy (PAP): Long-term PGA use can cause iris pigment darkening (especially in mixed-color irides), eyelash lengthening and darkening, periorbital skin hyperpigmentation, and deepening of the upper eyelid sulcus due to orbital fat atrophy. These changes may be long-lasting or permanent, so counsel patients early, especially when treating unilateral disease where asymmetry becomes noticeable.
Adding a second mechanism when monotherapy is insufficient
If first-line therapy does not achieve target IOP, additional classes are introduced stepwise. Selection should consider expected IOP effect, dosing burden, preservative exposure, systemic contraindications, and impact on the ocular surface.
- Beta blockers: Timolol, levobunolol, and betaxolol reduce aqueous production. Timolol (non-selective) is generally avoided in asthma, significant COPD, bradycardia, and certain cardiac conduction disorders due to systemic absorption. Betaxolol (beta-1 selective) may be tolerated in some patients with mild reactive airway disease, but pulmonary caution still applies. Timolol is available in gel-forming solutions for once-daily dosing and reduced systemic absorption.
- Alpha-2 agonists: Brimonidine reduces aqueous production and may increase uveoscleral outflow. It carries a notable rate of allergic conjunctivitis with chronic use (up to ~15–25% of patients) and should be used cautiously or avoided in young children due to CNS depression risk. Some data suggest possible neuroprotective properties, though this has not changed primary clinical management.
- Topical carbonic anhydrase inhibitors (CAIs): Dorzolamide (Trusopt) and brinzolamide (Azopt) reduce aqueous production via carbonic anhydrase inhibition. They are typically dosed twice or three times daily and are common second- or third-line additions. Sulfonamide allergy should be reviewed, and patients should be asked about metallic taste as a tolerability issue.
- ROCK inhibitors: Netarsudil 0.02% (Rhopressa) is a rho kinase inhibitor that lowers IOP by increasing trabecular meshwork outflow and reducing episcleral venous pressure, a unique dual mechanism among glaucoma drugs. Conjunctival hyperemia is the most common side effect and often the main tolerability barrier. Cornea verticillata (whorl-like corneal deposits) can occur but is typically reversible on discontinuation. Netarsudil is dosed once daily and is often added as a second or third agent when other classes have not reached target.
Fixed-combination drops to simplify complex regimens
When monotherapy is insufficient, moving to a fixed-combination drop can reduce bottle count, dosing complexity, and preservative exposure compared with separate bottles. This supports adherence and can reduce the ocular surface burden that accumulates with multiple preserved drops.
Common fixed combinations include dorzolamide/timolol (Cosopt), brimonidine/timolol (Combigan), brinzolamide/brimonidine (Simbrinza), and netarsudil/latanoprost (Rocklatan). Rocklatan combines a PGA with a ROCK inhibitor in a single once-daily drop and may be useful when both mechanisms are needed but the patient cannot manage multiple bottles.
Preservatives and ocular surface health
Most topical glaucoma drops contain benzalkonium chloride (BAK) as a preservative, which is directly toxic to the corneal and conjunctival epithelium with chronic exposure. Patients on long-term multi-drop regimens frequently develop signs of ocular surface disease: punctate epithelial erosions, conjunctival injection, reduced tear film stability, and lid margin changes. This can impair comfort, adherence, and even surgical outcomes if filtration surgery is eventually needed (BAK-related conjunctival scarring reduces bleb survival).
Preservative-free or BAK-free alternatives exist for several classes, including tafluprost (preservative-free PGA), timolol gel-forming solution, preservative-free dorzolamide/timolol, and selected brimonidine formulations using alternative preservatives such as Purite. When surface disease is a concern, switching to preservative-free options, reducing the number of drops via combination products, or considering laser or surgical alternatives can all help protect the ocular surface.
Selective laser trabeculoplasty (SLT) as an alternative path
SLT is increasingly considered as a first-line or early alternative to topical medication, not just a last resort before surgery. The LiGHT trial demonstrated that initial SLT achieved IOP control comparable to topical drops over three years, with many patients requiring no drops at all during that period. SLT can be repeated if the effect wanes and avoids the adherence, surface toxicity, and systemic side effect concerns of daily drops. It is most commonly applied in open-angle glaucoma and ocular hypertension. Discussion of SLT should be part of the initial treatment conversation, not reserved for medication failure. See the other medications page for pilocarpine use in angle-closure and pre-laser preparation.
Angle-closure: different pharmacology, different priorities
In primary angle-closure disease, the immediate priority is often to break the pupillary block mechanism with a laser peripheral iridotomy (LPI). IOP-lowering drops are used acutely to reduce pressure before the laser procedure and may be continued afterward if IOP remains elevated or if the angle does not fully open. Drug selection differs from POAG in important ways: PGAs are generally appropriate, but miotics (pilocarpine) play a more targeted role here than in open-angle disease by pulling the peripheral iris away from the trabecular meshwork. Avoid strong mydriatics in acute or untreated narrow-angle situations and review all systemic medications that could contribute to pupil dilation or angle crowding.
When to refer: surgery, MIGS, and co-management
Referral for surgical evaluation is appropriate when maximally tolerated medical and laser therapy fails to reach target IOP, when progression continues despite treatment, when the patient cannot maintain a tolerable drop regimen, or when ocular surface disease makes sustained topical therapy impractical. Minimally invasive glaucoma surgery (MIGS) procedures such as iStent, Hydrus, and Xen gel stent have broadened surgical options, particularly for mild to moderate disease and in combination with cataract surgery. Traditional filtering surgery (trabeculectomy, tube shunts) remains relevant for advanced or refractory disease. Co-management between optometry and ophthalmology helps ensure continuity of monitoring, adherence support, and timely escalation.
Systemic screening, technique, and follow-up
Because topical glaucoma medications can be systemically absorbed, review cardiovascular history, pulmonary disease, renal function, and current medications before prescribing agents such as beta blockers, alpha-2 agonists, or oral CAIs. Teach punctal occlusion (or eyelid closure for 1–2 minutes) and proper instillation technique to reduce systemic exposure and improve local efficacy. If multiple drops are needed, separate instillations by at least 5 minutes to avoid washout. Regular follow-up is essential to reassess target IOP, monitor for steroid response if concurrent steroid use is present, assess optic nerve status and visual field stability, and adjust therapy when progression is suspected.